However, pan‐HER TKIs inhibit both Her2 and EGFR, thus suppressing the Her2‐HSF1‐mutP53 interaction and leading to destabilization of the mutP53 protein in cancer cells.7, 24. This evidence concerns the gene EGFR and cancer.